Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis

Patel, Piyush M.; Philip, George; Yang, William H.; Call, Robert S.; Horak, Friedrich; LaForce, Craig; Gilles, L.; Garrett, Graigory; Dass, Sairia; Knorr, Barbara; Reiss, Theodore F.

doi:10.1016/s1081-1206(10)61018-6

Cited by 71 publications

(58 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results agree with those of previous studies, which show that monotherapy with montelukast [8] desloratadine [27] or levocetirizine [28][29][30] produces greater improvement in quality of life than placebo in patients affected by persistent and/or perennial allergic rhinitis.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Erdoğan

Şanlı²,

Paksoy³

et al. 2014

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

Objectives: This study aims to compare the effectiveness of desloratadine monotherapy and desloratadine plus montelukast combination therapy on quality of life in patients with persistent allergic rhinitis. Patients and Methods:This study consists of 40 patients (28 females, 12 males, mean age 29.8 years; range 17 to 44 years) referred to ear, nose, and throat outpatient clinic between May 2010 and September 2010. A six-week randomized, doubleblind, cross-sectional study was performed in two arms: In group 1, 20 patients received desloratadine (5 mg/d) alone; in group 2, 20 patients received desloratadine (5 mg) plus montelukast (10 mg) combination therapy. Quality of life was assessed on the day before starting treatment and on the last day of each treatment period using the Rhinoconjunctivitis Quality of Life Questionnaire and Nighttime Symptom Scores. Results:In group 1, the mean quality of life scores before and after treatment were 3.17 and 2.43, respectively. In group 2, the mean quality of life scores before and after treatment were 2.94 and 1.73, respectively. Conclusion:Desloratadine plus montelukast combination therapy may have a positive impact on quality of life, sleep symptoms in particular.Keywords: Desloratadine; montelukast; persistent allergic rhinitis; quality of life.Amaç: Bu çalışmada inatçı alerjik rinit hastalarında desloratadin monoterapisi ve desloratadin artı montelukast kombinasyon tedavisinin yaşam kalitesi üzerine etkinliği karşılaştırıldı. Bulgular: Grup 1'de tedavi öncesi ve sonrası ortalama yaşam kalitesi skoru, sırasıyla 3.17 ve 2.43 idi. Grup 2'de ise, tedavi öncesi ve sonrası ortalama yaşam kalitesi skoru, sırasıyla 2.94 ve 1.73 idi.Sonuç: Desloratadin artı montelukast kombinasyon tedavisinin, özellikle uyku semptomları olmak üzere, yaşam kalitesi üzerine olumlu bir etkisi olabilir.Anahtar Sözcükler: Desloratadin; montelukast; inatçı allerjik rinit; yaşam kalitesi.

show abstract

Section: Discussionsupporting

confidence: 92%

“…[6,7] Montelukast, a leukotriene receptor antagonist, significantly improves daytime and nighttime symptoms in patients with allergic rhinitis and is now an approved therapy for allergic rhinitis. [8] This study compares desloratadine monotherapy and combination montelukast with desloratadine on quality of life in allergic rhinitis.…”

mentioning

confidence: 99%

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Erdoğan

Şanlı²,

Paksoy³

et al. 2014

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

show abstract

“…Montelukast is equally effective in patients exposed to low and high pollen counts (1523). In one study of perennial rhinitis, montelukast was found to be superior to placebo (1522), but in another study its effects were not superior to placebo and were similar to cetirizine after 1 month of treatment (1587). In studies carried out on patients with seasonal allergic rhinitis and asthma, montelukast was found to improve nasal and bronchial symptoms (1588,1589).…”

Section: Pharmacodynamicsmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,859

1,761

View full text Add to dashboard Cite

“…In many sudies, it has been reported that leukotriene receptor antagonists are more effective than placebo, equivalent to oral H1-antihistaminics and inferior to intranasal glucocorticosteroids in the treatment of seasonal allergic rhinitis [18][19][20][21]. In one study of perennial rhinitis, montelukast was found to be superior to placebo [22], but in another study its effects were not superior to placebo and were similar to cetirizine after 1 month of treatment [23]. It has also been reported that the combination of oral H1-antihistaminics and leukotriene receptor antagonists does not increase the efficacy of any single drug and is less effective than intranasal corticosteroids [24][25][26].…”

Section: Discussionmentioning

confidence: 99%

The Effect of Combined Medical Treatment on Quality of Life in Persistent Allergic Rhinitis

Tatar

Sürenoğlu

Özdek

et al. 2012

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Allergic rhinitis may significantly affect the patients' quality of life. The aim of this study was to compare the effects of nasal steroids alone, to nasal steroids plus Levocetirizine or Montelukast, on quality of life in persistent allergic rhinitis. This is a prospective, randomized study and included 56 patients with moderate to severe persistent allergic rhinitis. All patients had house dust mite allergy on skin prick test and we divided the patients into three groups. 1 month long medical treatment was; topical Mometasone furoate 200 mcg/day in the first group (n:14), Mometasone furoate 200 mcg/day plus oral Levocetirizine 5 mg/day in the second group (n:21), and Mometasone furoate 200 mcg/ day plus oral Montelukast 10 mg/day in the third group (n:21). We evaluated the patients before treatment and at the first month after treatment with mini rhinoconjunctivitis quality of life questionnaire (miniRQLQ) and nasal symptom scores. In the first group nasal symptom and mini RQLQ scores were not improved but in second and third group, both scores were improved significantly (p \ 0.05). Nasal obstruction symptom score was better in the third group after treatment (p \ 0.01), but other nasal symptom scores (rhinorrhea, sneezing and nasal itching) were better in the second group (For each symptom p \ 0.05). Improvement of quality of life scores in the second group were better than the third group (p \ 0.05). In persistent allergic rhinitis, combination of levocetirizine or montelukast to nasal steroids was better than the topical mometasone furoate alone in terms of quality of life.

show abstract

Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis

Cited by 71 publications

References 25 publications

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

The Effect of Combined Medical Treatment on Quality of Life in Persistent Allergic Rhinitis

Contact Info

Product

Resources

About